WHO ICTRP trial
Comparing the Efficacy of Aripiprazole with other Second-Generation…
IRCT20181026041468N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20181026041468N1 |
|---|---|
| Public title | Comparing the Efficacy of Aripiprazole with other Second-Generation Antipsychotics in smoke cessation of inpatient Manic sufferers |
| Scientific title | Comparing the Efficacy of Aripiprazole with other Second-Generation Antipsychotics in smoke cessation of inpatient Manic sufferers |
| Primary sponsor | Arak University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 4 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Condition 1: Bipolar mood disorder. Condition 2: Nicotine dependence. Persistent mood [affective] disorders Nicotine dependence |
| Interventions | Intervention 1: Intervention group: In the intervention group, treatment with Aripiprazole will initiate at baseline dose of 5 to 15 mg per day. After two weeks the dose may increase by 5 mg, as well as at weeks 4 and 6. This can be 5 mg… |
| Registration date | Jul 4, 2019 |
| Target size | 40 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: